The global PD-L1 biomarker testing market share analysis is on a trajectory of rapid growth, with sales projected to reach USD 777.2 million by 2025. This expansion is fueled by the increasing use of immunotherapy drugs for treating various cancers, including non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma. As precision medicine gains …